CN111850007B - Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application - Google Patents

Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application Download PDF

Info

Publication number
CN111850007B
CN111850007B CN202010730981.0A CN202010730981A CN111850007B CN 111850007 B CN111850007 B CN 111850007B CN 202010730981 A CN202010730981 A CN 202010730981A CN 111850007 B CN111850007 B CN 111850007B
Authority
CN
China
Prior art keywords
mutant
calcium ion
seq
ion concentration
low calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010730981.0A
Other languages
Chinese (zh)
Other versions
CN111850007A (en
Inventor
汪俊卿
王大涛
李楠
范翰
王瑞明
李丕武
姜彦君
王子睿
杨翠平
薛乐
张晨曦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu University of Technology
Original Assignee
Qilu University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu University of Technology filed Critical Qilu University of Technology
Priority to CN202010730981.0A priority Critical patent/CN111850007B/en
Publication of CN111850007A publication Critical patent/CN111850007A/en
Application granted granted Critical
Publication of CN111850007B publication Critical patent/CN111850007B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Abstract

A small-fiber docking protein combination mutant 36864 suitable for low calcium ion concentration is a small-fiber docking protein DocA, the nucleotide sequence is shown as SEQ ID No.3, and fixed-point mutation is carried out to obtain a docking protein combination mutant 36864 suitable for low calcium ion concentration, and the nucleotide sequence is shown as SEQ ID No. 1; the dockerin mutant is suitable for low calcium ion concentration of 10‑7M‑10‑4The condition of M interacts with mucin; further suitable for low calcium ion concentration of 10‑7M‑10‑6The condition of M interacts with mucin; is suitable for interaction with mucin in an intracellular environment; solves the problem that the existing fiber body element can not be self-assembled under the condition of low calcium ion concentration.

Description

Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application
Technical Field
The invention belongs to the field of genetic engineering and enzyme engineering, and particularly relates to a cellosome docking protein combination mutant 36864 suitable for low calcium ion concentration and application thereof.
Background
The cellulosome is a natural extracellular multienzyme self-assembly system which can organize and coordinate a plurality of enzyme components to efficiently catalyze and degrade lignocellulose in a synergetic way, the cellulosome is not only a supermolecule extracellular protein complex formed by the interaction between foot rest protein, cellulase, hemicellulase and other enzymes through an assembly module, namely fibronectin and docking protein, but also a nanometer machine which is composed of a plurality of non-catalytic and catalytic subunits and has a complex structure, the existence of the nanometer machine can greatly improve the degradation efficiency of cellulose, and researches show that the efficiency of the cellulosome for hydrolyzing cellulose is 6 times of that of free enzyme, and the cellulosome can be attached to the surface of bacterial cells and can be independently released as a cellfree cellulosome. The fibroid consists essentially of two parts: dockerin (Doc) containing enzymes or other accessory proteins and fibronectin (cohesin, Coh) containing structural proteins.
The research of the prior art finds that a sequence D rich in hydrophilic amino acid exists in a cellulosome element Doc1 D/N 3D/N 5 D/N9 D12And the affinity of Doc and Coh from different producer species for each other can be altered by mutating the sequence between S688-T689 and S720-T721 therein, see the documents [ Page' S. PROTECTINS: Structure, Function, and Genetics,1997,29: 517-527; MECHANY PROTEINS Structure, Function, and Genetics 2000,39: 170-](ii) a The binding between Coh and Doc in the prior art requires large amounts of calcium ions (concentrations of 0.5mM to 2mM), see literature [ bulb, Journal of Biological Chemistry,2018,293 (11); xu, Biotechnol Biofuels,2013, 6(1):126](ii) a Even higher calcium ion concentrations (2 mM-10 mM), see literature [ MECHANY. PROTECTINS: Structure, Function, and Genetics,2000,39: 170-]。
Due to metabolic requirements, the calcium ion concentration in the cells of microorganisms at rest is generally only 10-7M～10-6M, much lower than the extracellular concentration (1mM), see the literature [ Van Qian, Chinese Tropical medicine, 2014,14(11):1309-1313]Therefore, the cellulosome can only act at high calcium ion concentration (. gtoreq.1 mM) in the prior art, which fails to provide a solution that can be at 10 ≥ mM-7M ～10-6The cellosome element that can be efficiently assembled under M condition cannot be provided in a wide range of calcium ion environment (calcium ion concentration 10)-7M-2 mM), and further fails to provide a cellulosome element capable of functioning in biological cells (calcium ion concentration 10 or less)-6M) assembled cellosome elements.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a small-body docking protein combined mutant 36864 suitable for low calcium ion concentration and application thereof.
The invention provides a cellosome dockerin mutant suitable for low calcium ion concentration and application thereof, solves the problem that the existing cellosome element cannot be self-assembled under low calcium ion concentration (such as in cells), and provides a mutant suitable for a wide-range calcium ion environment (calcium ion concentration 10)-7M～2×10-3M) a working cellulosome dockerin mutant.
The technical scheme of the invention
A small-fiber docking protein combined mutant 36864 suitable for low calcium ion concentration is a small-fiber docking protein DocA, the nucleotide sequence is shown as SEQ ID No.3, and site-directed mutagenesis is performed to obtain the docking protein combined mutant 36864 suitable for low calcium ion concentration, and the nucleotide sequence is shown as SEQ ID No. 1.
A small-fiber docking protein combined mutant 36864 suitable for low calcium ion concentration is a small-fiber docking protein DocA, the amino acid sequence is shown as SEQ ID No.4, and site-directed mutagenesis is performed to obtain the docking protein combined mutant 36864 suitable for low calcium ion concentration, and the amino acid sequence is shown as SEQ ID No. 2.
The DocA is derived from Clostridium thermocellum (Clostridia thermocellum) (GenBank:2CCL _ B), the nucleotide sequence of the DocA is shown as SEQ ID NO.3, and the amino acid sequence of the DocA is shown as SEQ ID NO. 4.
D in the above amino acid sequence6VNGDGTINSTD17Mutation to D6VDGSGRINSTD17； D40VDKNGSINAAD51Mutation to D40TSNNGTINAAD51。
The preparation method of the fibrosome docking protein combined mutant 36864 comprises the following steps:
carrying out site-directed mutagenesis by taking a nucleotide sequence in the docking protein as shown in SEQ ID NO.3 to obtain a docking protein combination mutant 36864, designing a site-directed mutagenesis primer on the basis of the nucleotide sequence as shown in SEQ ID NO.1, carrying out PCR by taking a pET28a (+) vector carrying a cellosome docking protein gene as a template to construct a recombinant mutant plasmid, transforming the mutant plasmid into escherichia coli BL21(DE3), selecting a positive clone for fermentation, collecting thalli after the fermentation is finished, crushing the thalli, and purifying to obtain the cellosome docking protein mutant.
According to the preferable preparation method, the dockerin is mutated into a dockerin combination mutant 36864 by the dockerin with an amino acid sequence shown as SEQ ID No.4, and the amino acid sequence is shown as SEQ ID No. 2.
Preferably, in the above preparation method, after the fermentation is completed, the bacterial cells are collected by centrifugation, disrupted by sonication, and purified by affinity chromatography to obtain the mutant of the fibrosome dockerin.
According to the preferable preparation method, the PCR amplification of the dockerin combined mutant 36864 is carried out, the plasmid is divided into an AB section and a BA section, the AB section amplification primers are F1 and R2, the BA section amplification primers are F2 and R1, and the AB section and the BA section are respectively amplified by using the amplification primers; the nucleotide sequence of the PCR amplification primer is as follows:
F1：GTG gat GGT agc GGT cgt ATTAATAGCACCGAT SEQ ID NO.9；
R1：TTAAT acg ACC gct ACC atc CACGTCACCCAGCA SEQ ID NO.10；
F2：CGAT accagcaat AATGGC acc ATTAATGCCGCCGATGTTCT SEQ ID NO.11；
R2：ATTAAT ggt GCCATT attgctggt ATCGGCACGGGCTTTGGCA SEQ ID NO.12。
the lower case letters in the primer nucleotide sequence are mutation sites.
Further preferably, in the preparation method, the PCR reaction system:
plasmid DocA-pET28a vector template 1. mu.L, forward mutation primer F1/F22. mu.L, reverse mutation primer R2/R12. mu.L, 2 xMax Buffer 25. mu.L, dNTP 4. mu.L, DNA Polymerase 1. mu.L, ddH2O 15μL。
Further preferably, in the preparation method, the PCR reaction conditions are as follows:
pre-denaturation at 95 ℃ for 3 min; 15sec at 95 ℃, 15sec at 60 ℃, 3min at 72 ℃ and 18 cycles; extension was supplemented at 72 ℃ for 7 min.
According to the invention, preferably, after the PCR reaction is completed, the original template in the PCR amplification product needs to be digested by Dnp I enzyme, and after the digestion reaction system is mixed uniformly, the original template is digested for 2 hours at 37 ℃.
Further preferably, the digestion system:
PCR amplification product 40. mu.L, Dnp I enzyme 1. mu.L.
Preferably, the digestion product is detected by DNA gel electrophoresis, and the AB section and the BA section are respectively recovered by using a glue recovery kit after detection.
According to the invention, preferably, the recovered AB section and BA section are recombined by utilizing Exnase II, the reaction product is the vector to be transformed, and the recombination reaction system is as follows:
ddH2o10. mu.L, 5 XCE II Buffer 4. mu.L, product 2. mu.L recovered in AB, product 2. mu.L recovered in BA, and Exnase II 2. mu.L.
Further preferably, the transformation of the mutant vector comprises transforming the above-mentioned vector to be transformed into E.coli BL21(DE3) cells, and plating the transformant with a medium containing kanamycin (50. mu.g.mL)-1) After overnight culture at 37 ℃ on the LB solid medium, single colonies are picked up, sequencing verification is carried out, and positive mutants are screened to obtain recombinant Escherichia coli 36864-BL 21.
More preferably, the mutant is expressed and purified by inoculating the correctly identified strain in liquid LB medium containing kanamycin (50. mu.g.mL-1), culturing overnight at 37 ℃, transferring to liquid LB medium, culturing at 37 ℃ until OD 600. apprxeq.1, adding to a final concentration of 1. mu.m.mL-1The IPTG of (3), was induced at 26 ℃ for 8 hours at 200rpm, the induced cells were collected, then the cells were resuspended in 2 × PBS buffer, disrupted by ultrasonication, centrifuged at 10000rpm for 10min, the protein in the supernatant after centrifugation was purified using a nickel ion affinity column, and desalted by dialysis using PBS-EP + buffer, to obtain purified fibro-body-dockerin combinatorial mutant 36864.
The application of the fibrosome docking protein combination mutant 36864 in constructing a protein complex by interacting with the cadherin.
According to the invention, the use of the dockerin combination mutant 36864 for constructing protein complexes with mucin at low calcium ion concentrations is preferred.
Further preferably, the low calcium ion concentration is 10-7M-10-3M；
Further preferably, the low calcium ion concentration is 10-7M-10-4M；
Further preferably, the low calcium ion concentration is 10-7M-10-6M。
According to a preferred embodiment of the present invention, the dockerin combination mutant 36864 is used in constructing a protein complex by intracellular interaction with mucin.
The invention has the beneficial technical effects
1. The fibrosome dockerin combined mutant 36864 provided by the invention can reduce the calcium ion demand of the key element dockerin of the fibrosome, and realize the calcium ion environment in a wide range (the calcium ion concentration is 10)-7M～2×10-3M) effective binding to the fibronectin of the cellulosome and realizes the calcium ion concentration of 10-7M～10-6Under the condition of M, the protein can be effectively assembled with the fibronectin.
2. The mutant of the fibronectin realizes the effective assembly with the fibronectin in cells.
3. The invention provides a new method and a new way for assembling the intracellular multienzyme complex, and has wide application prospect.
Drawings
FIG. 1 is a schematic diagram of the separation of the plasmid into AB and BA segments in example 1;
FIG. 2 is a bar graph of intracellular interaction analysis of the mutant fibronectin and fibronectin corresponding to example 4;
FIG. 3 is a line graph showing the binding capacity of the mutant fibronectin of example 5 to mucin at different calcium ion concentrations.
Detailed Description
The invention is further illustrated with reference to specific examples, without limiting the scope of protection.
Sources of materials
The vectors DocA-pET28a and CohA-pET28a were extracted from Escherichia coli DH 5. alpha. or stored in the Escherichia coli DH 5. alpha. in the laboratory, which is an important laboratory in microbial engineering, Shandong, university of Qilu Industrial science, and those skilled in the art can construct the vectors according to the prior art or purchase them from the laboratory.
The contents of the examples, which are not specified in specific conditions, were carried out under conventional conditions; the reagents or instruments used are not indicated by the manufacturer, and are all common commercial products.
Example 1
Mutant primer design and mutant vector construction
Primer design of dockerin mutants was performed using dockerin DocA (vector DocA-pET28a, nucleotide sequence shown in SEQ ID NO. 13) ligated to pET28a (+) vector, respectively, as a template (see Table one). Wherein the DocA is derived from Clostridium thermocellum (Clostridia thermocellum) (GenBank:2CCL _ B), and the optimization of nucleotide sequence is carried out according to the codon preference of Escherichia coli, the DocA nucleotide sequence is shown as SEQ ID NO.3, and the DocA amino acid sequence is shown as SEQ ID NO. 4.
Watch-two-site mutation primer watch
Figure BDA0002603331120000051
Note: lower case letters are mutation sites.
The plasmid is divided into an AB section and a BA section by taking a site A to be mutated and a site B to be mutated as boundaries, and the AB section and the BA section are shown in a figure 1.
The AB fragment and BA fragment were amplified separately using Phanta enzyme.
The AB section amplification primers are F1 and R2, the BA section amplification primers are F2 and R1, the template plasmid is firstly digested by Dpn I after amplification, and the AB section and the BA section are respectively recovered after digestion. The PCR process, the Dpn I digestion process and the gel recovery process are as follows:
(1) and (3) PCR reaction, namely accurately adding the plasmid DocA-pET28a, the designed mutation primer, and the enzyme and buffer required by PCR according to the addition amount of each component in the second table, preparing PCR reaction solution of an experimental group (namely a double-site mutation group), and carrying out PCR reaction according to a third-table PCR reaction program.
Surface two-site mutation PCR reaction system
Figure BDA0002603331120000052
TABLE III PCR reaction conditions
Figure BDA0002603331120000053
Figure BDA0002603331120000061
(2) After the digestion of the amplification product, namely the PCR reaction is finished, in order to prevent the interference of a false positive transformant formed by the template plasmid DocA-pET28a after transformation, the plasmid DocA-pET28a is digested before a recombination cyclization experiment, the enzyme for digestion is Dpn I enzyme, the digestion reaction system is shown in the table four, and after the system is well configured and fully mixed, the system is digested for 2 hours at the temperature of 37 ℃.
TABLE IV digestion System
Figure BDA0002603331120000062
(3) And (3) recovering glue of the AB section and the BA section, namely performing DNA gel electrophoresis detection on the digestion product, and respectively recovering the AB section and the BA section by using a glue recovery kit after detection.
(4) And carrying out recombination reaction on the recovered AB section and BA section by utilizing Exnase II, adding each component in a sterile 200 mu L centrifugal tube in an ice bath according to the adding proportion of each component in the table five, gently blowing and uniformly mixing by using a pipette gun after the addition is finished, centrifuging for a short time by using a small centrifuge to avoid low recombination efficiency caused by residual components on the wall of the test tube, placing the centrifuged test tube in a metal water bath at 37 ℃ for accurate reaction for 30min, immediately placing the test tube in an ice box after the reaction is finished, and carrying out ice water bath for 5 min. The reaction product was either directly converted into competent BL21(DE3) or refrigerated in a refrigerator at-20 ℃.
TABLE V recombination reaction System
Figure BDA0002603331120000063
Mutant vector transformed host bacteria-taken out from-80 deg.C refrigeratorAppropriate amount of DH 5. alpha. competent cells were thawed by rapidly placing on ice, and after thawing, the procedure was performed according to the DH 5. alpha. competent transformation instructions, taking care that the time when the competent cells were just thawed was selected when the recombinant product was added, the time when the competent cells were just thawed was on ice except for heat shock, and the experimental work was gentle because the competent cells were easily inactivated, 400. mu.L of liquid LB medium (1% peptone, 1% yeast extract, 0.5% NaCl, and the balance water) was added to a clean bench after ice-bath, and then thawed in a shaker at 37 ℃ for about 1h, and after thawing, centrifugation at 4000rpm for 5 minutes was performed, and after removing 400. mu.L of supernatant, the balance 200. mu.L was directly applied to a medium containing kanamycin (50. mu.g.mL)-1) After overnight culture on the solid medium (1% peptone, 1% yeast extract, 0.5% NaCl, 2% agar, balance water), a single colony was picked up and cultured, and sent to sequencing company for sequencing and verifying the amino acid sequence D in DocA6VNGDGTINSTD17Mutation to D6VDGSGRINSTD17；D40VDKNGSINAAD51Mutation to D40TSNNGTINAAD51(ii) a Screening out positive clones to obtain recombinant Escherichia coli 36864-BL 21.
Example 2
Inducible expression and purification of muteins
The correctly verified strain was inoculated to a strain containing kanamycin (50. mu.g.mL)-1) The cultured cells were cultured overnight at 37 ℃ in 50mL of liquid LB medium, and then transferred to a new 50mL of liquid LB medium at 37 ℃ in an amount of 2% by volume, and cultured to OD600When the concentration is approximately equal to 1, the mixture is added until the final concentration is 1 mu m.mL-1The IPTG was induced in a shaker at 26 ℃ and 200rpm for 8 hours, and the induced cells were collected. The induced cells were resuspended in 10mL 2 XPBS buffer, disrupted by ultrasonication, centrifuged at 10000rpm for 10min, and the protein in the supernatant after centrifugation was purified by a nickel ion affinity column and desalted by dialysis using PBS-EP + buffer (from GE). Purified cellulosome dockerin combinatorial mutant 36864 was obtained.
Example 3
Construction and induced expression of expression vector of fibronectin
Transformation of the CohA-pET28a vector was carried out in the same manner as in example 1 using pET28a (+) vector to which the cellulosome fibronectin CohA was ligated, and similarly transformation of DocA-pET28a vector was prepared to obtain recombinant E.coli DocA-BL 21 and CohA-BL21, and inducible expression and purification of genes were carried out in the same manner as in example 2. Purified fibrosome mucin CohA, fibrosome dockerin DocA was obtained. Wherein the cellulosome mucin CohA is derived from a Clostridium thermocellum (Clostridium thermocellum) scaf gene (GenBank: MH049738.1), the nucleotide sequence of the CohA is shown as SEQ ID NO.5, and the amino acid sequence of the CohA is shown as SEQ ID NO. 6.
Example 4
Intracellular interaction analysis of fibronectin and fibronectin
The intracellular fibrosome dockerin-mucin interaction was characterized using bimolecular fluorescence complementation (BIFC). The BIFC uses fluorescent protein eYFP, the nucleotide sequence of the eYFP is shown as SEQ ID NO.7, and the amino acid sequence of the eYFP is shown as SEQ ID NO. 8. The double expression plasmid pETDuet-1 of Escherichia coli is taken as a vector, and the fluorescent protein eYFP is split into two sections of polypeptides from amino acid position 155, namely eYN (1-155) and eYC (156-238).
The two fluorescent complementary fragments are respectively connected with the dockerin and the cohesin through flexible connecting peptide SGGGSGGGSGGS, and are fused with the proteins according to a certain sequence, and the two fluorescent complementary fragments are taken as two independent coding proteins to be simultaneously expressed on pETDuet-1. The plasmid pETDuet-1-eYN (1-155) -CohA-DocA-eYC (156-238) was obtained and transformed by the transformation method described in example 1. Interaction of the dockerin with the fibronectin brings the eYN (1-155) and eYC (156-238) fragments fused to it in close spatial proximity to each other, which brings the two non-fluorescing fragments back together to reform the fluorescent protein eYFP, which is excited under 488nm light, said fusion sequence being synthesized by Biotechnology (Shanghai) GmbH.
Constructing recombinant plasmids corresponding to the dockerin combination mutant 36864 and the mucin CohA pair in the same way; transformation of the pETDuet-1 vector was performed as in example 1.
Finally, coexpression recombination BL21 was obtained, pETDuet-1-eYN (1-155) -CohA-DocA-eYC (156-238) and BL21, pETDuet-1-eYN (1-155) -CohA-36864-eYC (156-238), and the blank control was E.coli BL21, and the gene was expressed by induction in the same manner as in example 2. The Abs value (i.e., fluorescence intensity value) was quantitatively analyzed by fluorescent protein using a microplate reader, and the results are shown in fig. 2.
FIG. 2 shows that the fluorescence excitation values of DocA fused with BIFC protein and control bacteria are close, indicating that the non-mutated DocA and CohA can not effectively interact in the low calcium ion environment in the cell. The fluorescence excitation value of the dockerin combined mutant 36864 fused with the BIFC protein is obviously higher than that of DocA and a control bacterium, which shows that the requirement of the dockerin of key elements of the cellosome on calcium ions is reduced by mutating the sequence with the calcium ion binding function in the cellosome dockerin, and the dockerin is promoted to be in a low calcium ion concentration (the calcium ion concentration is less than or equal to 10) in cells-6M) and the fibronectin to assemble, and lays a foundation for the intracellular assembly of the fibrosomes.
Example 5
Analysis of binding Capacity of Fibrosomal docking protein and mucin at different calcium ion concentrations
Figure BDA0002603331120000081
Analyzing the binding capacity between the mutant of the cellosome docking protein and the fibronectin with different calcium ion concentrations by using a biomacromolecule interaction instrument, selecting a proper CM5 chip as an anchoring chip, calculating the approximately required concentration of the protein CohA according to the formula, performing gradient dilution on acetic acid-sodium acetate buffer solutions with different pH values according to the approximately protein concentration to serve as the protein to be anchored, determining the optimal anchoring concentration and pH value according to the anchoring condition, and then anchoring the CohA according to the fibronectin in Biacore micromolecule application operation manual. The anchored chip was loaded into a molecular interaction apparatus in 1 XPBS-HP + solution (available from GE), and the dockerin and mutant were diluted to nearly the same anchoring concentration as the protein CohA and combined with different concentrations of CaCl2Standing at 4 deg.CAfter 30min, the binding was determined on the machine and judged according to the AbsResp value (i.e., the binding interaction intensity value), and the results are shown in fig. 3 (table six). This result indicates that dockerin combinatorial mutant 36864 has calcium concentration > 10 relative to unmutated dockerin DocA-4The binding capacity of M and the mucoprotein CohA is obviously enhanced, and the result simultaneously discovers that the dockerin combination mutant 36864 has the calcium ion concentration less than or equal to 10-4M still has strong binding capacity with the mucoprotein CohA, which indicates that the dockerin combined mutant 36864 can be used in a wide range of calcium ion environments (calcium ion concentration is 10)-7M～2×10-3) Play a role in the process. Furthermore, although the unmutated dockerin DocA was found to have a calcium ion concentration of 10 or less-6M has a certain binding signal with the mucin CohA, and the AbsResP value is about 200, but the result of the binding example 4 shows that the binding can not exist continuously and stably, and the binding is invalid, and the mutant protein and the mucin AbsResP value exceeds 400, which shows that the two proteins can be stably combined together. Research finds that the dockerin combination mutant 36864 has calcium ion concentration over 10-3The activity of M is reduced to a certain extent, which shows that the structure of the mutant site region can be changed when the calcium ion concentration is too high, and the performance of the docking capability of the mutant protein is influenced.
Analysis of binding ability of the mutants to mucin at different calcium ion concentrations
Figure 1
The fibrosome dockerin combined mutant 36864 provided by the invention can reduce the calcium ion demand of the key element dockerin of the fibrosome, and realize the calcium ion environment in a wide range (the calcium ion concentration is 10)-7M～2×10-3M) effective binding to the fibronectin of the cellulosome and realizes the calcium ion concentration of 10-7M～10-6Can be effectively assembled with the fibronectin under the condition of M; the effective assembly of the adhesion protein with the cellulosome in the cell is realized; the invention provides a novel method and a novel way for assembling intracellular multi-enzyme complexes, and has wide application rangeThe application prospect of (1).
The fibrosome docking protein in the prior art contains calcium ion binding sites, the formation of the active structure of the fibrosome docking protein needs the support of calcium ions, the active structure interacts with the calcium ions and needs high calcium ion concentration, and then the fibrosome docking protein forms a specific conformation and interacts with the fibrosome fibronectin, and then the assembly of the whole fibrosome is completed. The dockerin combined mutant 36864 obtained by multi-site fixed-point mutation can form a specific conformation under the condition of low calcium ion concentration, and interacts with the fibronectin of the cellulosome to complete the assembly of the whole cellulosome; and interaction assembly can be realized in cells; which would not have been expected by the person skilled in the art.
SEQUENCE LISTING
<110> university of Qilu Industrial science
<120> fibrosome docking protein combined mutant 36864 applicable to low calcium ion concentration and application
<160> 13
<170> PatentIn version 3.5
<210> 1
<211> 261
<212> DNA
<213> Artificial sequence
<400> 1
atggtgctgc tgggtgacgt ggatggtagc ggtcgtatta atagcaccga tctgaccatg 60
ctgaaacgtt ctgttctgcg tgccattacc ctgaccgatg atgccaaagc ccgtgccgat 120
accagcaata atggcaccat taatgccgcc gatgttctgc tgctgtctcg ctatctgctg 180
cgtgttattg ataaaggagg aggcggctcg ggaggaggcg gctcgggagg aggcggctcg 240
catcatcatc atcatcatta a 261
<210> 2
<211> 86
<212> PRT
<213> Artificial sequence
<400> 2
Met Val Leu Leu Gly Asp Val Asp Gly Ser Gly Arg Ile Asn Ser Thr
1 5 10 15
Asp Leu Thr Met Leu Lys Arg Ser Val Leu Arg Ala Ile Thr Leu Thr
20 25 30
Asp Asp Ala Lys Ala Arg Ala Asp Thr Ser Asn Asn Gly Thr Ile Asn
35 40 45
Ala Ala Asp Val Leu Leu Leu Ser Arg Tyr Leu Leu Arg Val Ile Asp
50 55 60
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
65 70 75 80
His His His His His His
85
<210> 3
<211> 261
<212> DNA
<213> Artificial sequence
<400> 3
atggtgctgc tgggtgacgt gaatggtgac ggtaccatta atagcaccga tctgaccatg 60
ctgaaacgtt ctgttctgcg tgccattacc ctgaccgatg atgccaaagc ccgtgccgat 120
gtggataaaa atggcagcat taatgccgcc gatgttctgc tgctgtctcg ctatctgctg 180
cgtgttattg ataaaggagg aggcggctcg ggaggaggcg gctcgggagg aggcggctcg 240
catcatcatc atcatcatta a 261
<210> 4
<211> 86
<212> PRT
<213> Artificial sequence
<400> 4
Met Val Leu Leu Gly Asp Val Asn Gly Asp Gly Thr Ile Asn Ser Thr
1 5 10 15
Asp Leu Thr Met Leu Lys Arg Ser Val Leu Arg Ala Ile Thr Leu Thr
20 25 30
Asp Asp Ala Lys Ala Arg Ala Asp Val Asp Lys Asn Gly Ser Ile Asn
35 40 45
Ala Ala Asp Val Leu Leu Leu Ser Arg Tyr Leu Leu Arg Val Ile Asp
50 55 60
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
65 70 75 80
His His His His His His
85
<210> 5
<211> 516
<212> DNA
<213> Artificial sequence
<400> 5
atgagcgacg gtgtggtggt ggaaattggc aaagtgaccg gtagcgtggg taccaccgtg 60
gaaattccgg tgtactttcg cggtgttccg agcaaaggta tcgccaactg cgattttgtt 120
ttccgctacg atccgaacgt gctggaaatc atcggcatcg atccgggtga catcatcgtg 180
gacccgaatc cgaccaagag cttcgatacc gccatttacc cggaccgcaa aatcattgtg 240
ttcctgttcg cagaggatag cggtaccggt gcctatgcca tcaccaaaga tggcgtgttc 300
gcaaagattc gcgcaaccgt gaaaagtagc gcaccgggct acattacctt tgacgaggtg 360
ggtggctttg ccgataacga tctggtggaa cagaaggtga gcttcattga cggtggcgtt 420
aacgtgggta atgccacacc gaccaagggt ggaggaggcg gctcgggagg aggcggctcg 480
ggaggaggcg gctcgcatca tcatcatcat cattaa 516
<210> 6
<211> 171
<212> PRT
<213> Artificial sequence
<400> 6
Met Ser Asp Gly Val Val Val Glu Ile Gly Lys Val Thr Gly Ser Val
1 5 10 15
Gly Thr Thr Val Glu Ile Pro Val Tyr Phe Arg Gly Val Pro Ser Lys
20 25 30
Gly Ile Ala Asn Cys Asp Phe Val Phe Arg Tyr Asp Pro Asn Val Leu
35 40 45
Glu Ile Ile Gly Ile Asp Pro Gly Asp Ile Ile Val Asp Pro Asn Pro
50 55 60
Thr Lys Ser Phe Asp Thr Ala Ile Tyr Pro Asp Arg Lys Ile Ile Val
65 70 75 80
Phe Leu Phe Ala Glu Asp Ser Gly Thr Gly Ala Tyr Ala Ile Thr Lys
85 90 95
Asp Gly Val Phe Ala Lys Ile Arg Ala Thr Val Lys Ser Ser Ala Pro
100 105 110
Gly Tyr Ile Thr Phe Asp Glu Val Gly Gly Phe Ala Asp Asn Asp Leu
115 120 125
Val Glu Gln Lys Val Ser Phe Ile Asp Gly Gly Val Asn Val Gly Asn
130 135 140
Ala Thr Pro Thr Lys Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
145 150 155 160
Gly Gly Gly Gly Ser His His His His His His
165 170
<210> 7
<211> 717
<212> DNA
<213> Artificial sequence
<400> 7
atgagcaagg gcgaggagct gttcaccggg gtggtgccca tcctggtcga gctggacggc 60
gacgtaaacg gccacaagtt cagcgtgtcc ggcgagggcg agggcgatgc cacctacggc 120
aagctgaccc tgaagttcat ctgcaccacc ggcaagctgc ccgtgccctg gcccaccctc 180
gtgaccacct tcggctacgg cctgcaatgc ttcgcccgct accccgacca catgaagctg 240
cacgacttct tcaagtccgc catgcccgaa ggctacgtcc aggagcgcac catcttcttc 300
aaggacgacg gcaactacaa gacccgcgcc gaggtgaagt tcgagggcga caccctggtg 360
aaccgcatcg agctgaaggg catcgacttc aaggaggacg gcaacatcct ggggcacaag 420
ctggagtaca actacaacag ccacaacgtc tatatcatgg ccgacaagca gaagaacggc 480
atcaaggtga acttcaagat ccgccacaac atcgaggacg gcagcgtgca gctcgccgac 540
cactaccagc agaacacccc catcggcgac ggccccgtgc tgctgcccga caaccactac 600
ctgagctacc agtccgccct gagcaaagac cccaacgaga agcgcgatca catggtcctg 660
ctggagttcg tgaccgccgc cgggatcact ctcggcatgg acgagctgta caagtaa 717
<210> 8
<211> 238
<212> PRT
<213> Artificial sequence
<400> 8
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35 40 45
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60
Gly Tyr Gly Leu Gln Cys Phe Ala Arg Tyr Pro Asp His Met Lys Leu
65 70 75 80
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140
Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Tyr Gln Ser Ala Leu Ser
195 200 205
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220
Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
225 230 235
<210> 9
<211> 33
<212> DNA
<213> Artificial sequence
<400> 9
gtggatggta gcggtcgtat taatagcacc gat 33
<210> 10
<211> 34
<212> DNA
<213> Artificial sequence
<400> 10
ttaatacgac cgctaccatc cacgtcaccc agca 34
<210> 11
<211> 42
<212> DNA
<213> Artificial sequence
<400> 11
cgataccagc aataatggca ccattaatgc cgccgatgtt ct 42
<210> 12
<211> 43
<212> DNA
<213> Artificial sequence
<400> 12
attaatggtg ccattattgc tggtatcggc acgggctttg gca 43
<210> 13
<211> 5528
<212> DNA
<213> Artificial sequence
<400> 13
tggcgaatgg gacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg 60
cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc 120
ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg 180
gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc 240
acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 300
ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc 360
ttttgattta taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta 420
acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaatttcag gtggcacttt 480
tcggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta 540
tccgctcatg aattaattct tagaaaaact catcgagcat caaatgaaac tgcaatttat 600
tcatatcagg attatcaata ccatattttt gaaaaagccg tttctgtaat gaaggagaaa 660
actcaccgag gcagttccat aggatggcaa gatcctggta tcggtctgcg attccgactc 720
gtccaacatc aatacaacct attaatttcc cctcgtcaaa aataaggtta tcaagtgaga 780
aatcaccatg agtgacgact gaatccggtg agaatggcaa aagtttatgc atttctttcc 840
agacttgttc aacaggccag ccattacgct cgtcatcaaa atcactcgca tcaaccaaac 900
cgttattcat tcgtgattgc gcctgagcga gacgaaatac gcgatcgctg ttaaaaggac 960
aattacaaac aggaatcgaa tgcaaccggc gcaggaacac tgccagcgca tcaacaatat 1020
tttcacctga atcaggatat tcttctaata cctggaatgc tgttttcccg gggatcgcag 1080
tggtgagtaa ccatgcatca tcaggagtac ggataaaatg cttgatggtc ggaagaggca 1140
taaattccgt cagccagttt agtctgacca tctcatctgt aacatcattg gcaacgctac 1200
ctttgccatg tttcagaaac aactctggcg catcgggctt cccatacaat cgatagattg 1260
tcgcacctga ttgcccgaca ttatcgcgag cccatttata cccatataaa tcagcatcca 1320
tgttggaatt taatcgcggc ctagagcaag acgtttcccg ttgaatatgg ctcataacac 1380
cccttgtatt actgtttatg taagcagaca gttttattgt tcatgaccaa aatcccttaa 1440
cgtgagtttt cgttccactg agcgtcagac cccgtagaaa agatcaaagg atcttcttga 1500
gatccttttt ttctgcgcgt aatctgctgc ttgcaaacaa aaaaaccacc gctaccagcg 1560
gtggtttgtt tgccggatca agagctacca actctttttc cgaaggtaac tggcttcagc 1620
agagcgcaga taccaaatac tgtccttcta gtgtagccgt agttaggcca ccacttcaag 1680
aactctgtag caccgcctac atacctcgct ctgctaatcc tgttaccagt ggctgctgcc 1740
agtggcgata agtcgtgtct taccgggttg gactcaagac gatagttacc ggataaggcg 1800
cagcggtcgg gctgaacggg gggttcgtgc acacagccca gcttggagcg aacgacctac 1860
accgaactga gatacctaca gcgtgagcta tgagaaagcg ccacgcttcc cgaagggaga 1920
aaggcggaca ggtatccggt aagcggcagg gtcggaacag gagagcgcac gagggagctt 1980
ccagggggaa acgcctggta tctttatagt cctgtcgggt ttcgccacct ctgacttgag 2040
cgtcgatttt tgtgatgctc gtcagggggg cggagcctat ggaaaaacgc cagcaacgcg 2100
gcctttttac ggttcctggc cttttgctgg ccttttgctc acatgttctt tcctgcgtta 2160
tcccctgatt ctgtggataa ccgtattacc gcctttgagt gagctgatac cgctcgccgc 2220
agccgaacga ccgagcgcag cgagtcagtg agcgaggaag cggaagagcg cctgatgcgg 2280
tattttctcc ttacgcatct gtgcggtatt tcacaccgca tatatggtgc actctcagta 2340
caatctgctc tgatgccgca tagttaagcc agtatacact ccgctatcgc tacgtgactg 2400
ggtcatggct gcgccccgac acccgccaac acccgctgac gcgccctgac gggcttgtct 2460
gctcccggca tccgcttaca gacaagctgt gaccgtctcc gggagctgca tgtgtcagag 2520
gttttcaccg tcatcaccga aacgcgcgag gcagctgcgg taaagctcat cagcgtggtc 2580
gtgaagcgat tcacagatgt ctgcctgttc atccgcgtcc agctcgttga gtttctccag 2640
aagcgttaat gtctggcttc tgataaagcg ggccatgtta agggcggttt tttcctgttt 2700
ggtcactgat gcctccgtgt aagggggatt tctgttcatg ggggtaatga taccgatgaa 2760
acgagagagg atgctcacga tacgggttac tgatgatgaa catgcccggt tactggaacg 2820
ttgtgagggt aaacaactgg cggtatggat gcggcgggac cagagaaaaa tcactcaggg 2880
tcaatgccag cgcttcgtta atacagatgt aggtgttcca cagggtagcc agcagcatcc 2940
tgcgatgcag atccggaaca taatggtgca gggcgctgac ttccgcgttt ccagacttta 3000
cgaaacacgg aaaccgaaga ccattcatgt tgttgctcag gtcgcagacg ttttgcagca 3060
gcagtcgctt cacgttcgct cgcgtatcgg tgattcattc tgctaaccag taaggcaacc 3120
ccgccagcct agccgggtcc tcaacgacag gagcacgatc atgcgcaccc gtggggccgc 3180
catgccggcg ataatggcct gcttctcgcc gaaacgtttg gtggcgggac cagtgacgaa 3240
ggcttgagcg agggcgtgca agattccgaa taccgcaagc gacaggccga tcatcgtcgc 3300
gctccagcga aagcggtcct cgccgaaaat gacccagagc gctgccggca cctgtcctac 3360
gagttgcatg ataaagaaga cagtcataag tgcggcgacg atagtcatgc cccgcgccca 3420
ccggaaggag ctgactgggt tgaaggctct caagggcatc ggtcgagatc ccggtgccta 3480
atgagtgagc taacttacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa 3540
cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat 3600
tgggcgccag ggtggttttt cttttcacca gtgagacggg caacagctga ttgcccttca 3660
ccgcctggcc ctgagagagt tgcagcaagc ggtccacgct ggtttgcccc agcaggcgaa 3720
aatcctgttt gatggtggtt aacggcggga tataacatga gctgtcttcg gtatcgtcgt 3780
atcccactac cgagatatcc gcaccaacgc gcagcccgga ctcggtaatg gcgcgcattg 3840
cgcccagcgc catctgatcg ttggcaacca gcatcgcagt gggaacgatg ccctcattca 3900
gcatttgcat ggtttgttga aaaccggaca tggcactcca gtcgccttcc cgttccgcta 3960
tcggctgaat ttgattgcga gtgagatatt tatgccagcc agccagacgc agacgcgccg 4020
agacagaact taatgggccc gctaacagcg cgatttgctg gtgacccaat gcgaccagat 4080
gctccacgcc cagtcgcgta ccgtcttcat gggagaaaat aatactgttg atgggtgtct 4140
ggtcagagac atcaagaaat aacgccggaa cattagtgca ggcagcttcc acagcaatgg 4200
catcctggtc atccagcgga tagttaatga tcagcccact gacgcgttgc gcgagaagat 4260
tgtgcaccgc cgctttacag gcttcgacgc cgcttcgttc taccatcgac accaccacgc 4320
tggcacccag ttgatcggcg cgagatttaa tcgccgcgac aatttgcgac ggcgcgtgca 4380
gggccagact ggaggtggca acgccaatca gcaacgactg tttgcccgcc agttgttgtg 4440
ccacgcggtt gggaatgtaa ttcagctccg ccatcgccgc ttccactttt tcccgcgttt 4500
tcgcagaaac gtggctggcc tggttcacca cgcgggaaac ggtctgataa gagacaccgg 4560
catactctgc gacatcgtat aacgttactg gtttcacatt caccaccctg aattgactct 4620
cttccgggcg ctatcatgcc ataccgcgaa aggttttgcg ccattcgatg gtgtccggga 4680
tctcgacgct ctcccttatg cgactcctgc attaggaagc agcccagtag taggttgagg 4740
ccgttgagca ccgccgccgc aaggaatggt gcatgcaagg agatggcgcc caacagtccc 4800
ccggccacgg ggcctgccac catacccacg ccgaaacaag cgctcatgag cccgaagtgg 4860
cgagcccgat cttccccatc ggtgatgtcg gcgatatagg cgccagcaac cgcacctgtg 4920
gcgccggtga tgccggccac gatgcgtccg gcgtagagga tcgagatctc gatcccgcga 4980
aattaatacg actcactata ggggaattgt gagcggataa caattcccct ctagaaataa 5040
ttttgtttaa ctttaagaag gagatatacc atggtgctgc tgggtgacgt gaatggtgac 5100
ggtaccatta atagcaccga tctgaccatg ctgaaacgtt ctgttctgcg tgccattacc 5160
ctgaccgatg atgccaaagc ccgtgccgat gtggataaaa atggcagcat taatgccgcc 5220
gatgttctgc tgctgtctcg ctatctgctg cgtgttattg ataaaggagg aggcggctcg 5280
ggaggaggcg gctcgggagg aggcggctcg catcatcatc atcatcatta agaattcgag 5340
ctccgtcgac aagcttgcgg ccgcactcga gcaccaccac caccaccact gagatccggc 5400
tgctaacaaa gcccgaaagg aagctgagtt ggctgctgcc accgctgagc aataactagc 5460
ataacccctt ggggcctcta aacgggtctt gaggggtttt ttgctgaaag gaggaactat 5520
atccggat 5528

Claims (18)

1. A small-fiber docking protein combination mutant 36864 suitable for low calcium ion concentration is characterized in that a small-fiber docking protein DocA is subjected to site-directed mutagenesis with a nucleotide sequence shown in SEQ ID No.3 to obtain a docking protein combination mutant 36864 suitable for low calcium ion concentration, wherein the nucleotide sequence is shown in SEQ ID No. 1.
2. A small-fiber docking protein combination mutant 36864 suitable for low calcium ion concentration is characterized in that a small-fiber docking protein DocA is subjected to site-directed mutagenesis with an amino acid sequence shown in SEQ ID No.4 to obtain a docking protein combination mutant 36864 suitable for low calcium ion concentration, wherein the amino acid sequence is shown in SEQ ID No. 2.
3. A method for preparing mutant 36864 according to any one of claims 1-2, comprising the steps of:
carrying out site-directed mutagenesis by taking a nucleotide sequence in the docking protein as shown in SEQ ID NO.3 to obtain a docking protein combination mutant 36864, designing a site-directed mutagenesis primer on the basis of the nucleotide sequence as shown in SEQ ID NO.1, carrying out PCR by taking a pET28a (+) vector carrying a cellosome docking protein gene as a template to construct a recombinant mutant plasmid, transforming the mutant plasmid into escherichia coli BL21(DE3), selecting a positive clone for fermentation, collecting thalli after the fermentation is finished, crushing the thalli, and purifying to obtain the cellosome docking protein mutant.
4. The method for preparing mutant 36864 of claim 3, wherein in the preparation method, the dockerin is mutated into dockerin combination mutant 36864 by the amino acid sequence shown in SEQ ID No.4, and the amino acid sequence shown in SEQ ID No. 2.
5. The method of claim 3, wherein the mutant 36864 is prepared by collecting thalli centrifugally after fermentation, performing ultrasonication on the thalli, and purifying by affinity chromatography to obtain a mutant of the fibrosome docking protein.
6. The method of claim 3, wherein PCR amplification of the dockerin combinatorial mutant 36864 comprises dividing the plasmid into AB and BA segments, wherein the AB segment amplification primers are SEQ ID NO.9 and SEQ ID NO.12, and the BA segment amplification primers are SEQ ID NO.11 and SEQ ID NO.10, and the AB segment and BA segment are amplified by using the amplification primers, respectively.
7. The method of claim 6, wherein the PCR reaction system comprises:
plasmid DocA-pET28a vector template 1. mu.L, forward mutation primer F1/F22. mu.L, reverse mutation primer R2/R12. mu.L, 2 xMax Buffer 25. mu.L, dNTP 4. mu.L, DNA Polymerase 1. mu.L, ddH2O15 μL。
8. The method of claim 6, wherein the PCR conditions for preparing mutant 36864 are:
pre-denaturation at 95 ℃ for 3 min; 15sec at 95 ℃, 15sec at 60 ℃, 3min at 72 ℃ and 18 cycles; extension was supplemented at 72 ℃ for 7 min.
9. The method of claim 6, wherein PCR is performed in the presence of mutant 36864DnpDigesting the original template in the PCR amplification product by the enzyme I, uniformly mixing a digestion reaction system, and digesting the mixture for 2 hours at 37 ℃.
10. The method of claim 9 for making mutant 36864,
the digestion system comprises:
40 mu L of PCR amplification product is obtained,Dnpi enzyme 1 u L.
11. The method of claim 9, wherein the digestion product is detected by DNA gel electrophoresis, and the AB and BA fractions are recovered by gel recovery kit after detection.
12. The method of claim 11, wherein the recovered AB segment and BA segment are recombined using Exnase II, the reaction product is a vector to be transformed, and the recombination reaction system is as follows:
ddH2o10. mu.L, 5 XCE II Buffer 4. mu.L, product 2. mu.L recovered in AB, product 2. mu.L recovered in BA, and Exnase II 2. mu.L.
13. The method of claim 12 for preparing mutant 36864, wherein the transformation of the mutant vector is carried out by transforming the said vector to be transformed into E.coli BL21(DE3) cells, and plating the transformant with 50 μ g/mL kanamycin-1After overnight culture at 37 ℃ on the LB solid medium, single colonies are picked up, sequencing verification is carried out, and positive mutants are screened to obtain recombinant Escherichia coli 36864-BL 21.
14. The method of claim 13, wherein the mutant 36864 is expressed and purified, and the correctly verified strain is inoculated to a strain containing kanamycin at 50. mu.g/mL-1The cultured cells were cultured overnight at 37 ℃ in the liquid LB medium of (1), and then transferred to a liquid LB medium and cultured at 37 ℃ until the OD 600. apprxeq.1, and then added to a final concentration of 1. mu.m.mL-1The IPTG of (3), was induced at 26 ℃ for 8 hours at 200rpm, the induced cells were collected, then the cells were resuspended in 2 × PBS buffer, disrupted by ultrasonication, centrifuged at 10000rpm for 10min, the protein in the supernatant after centrifugation was purified using a nickel ion affinity column, and desalted by dialysis using PBS-EP + buffer, to obtain purified fibro-body-dockerin combinatorial mutant 36864.
15. Use of the mutant 36864 of any one of claims 1-2 to interact with mucoprotein CohA at a low calcium ion concentration of 10 to construct a protein complex-7 M - 10-3M。
16. The use of claim 15, wherein the low calcium ion concentration is 10-7 M - 10-4M。
17. The use of claim 16, wherein the low calcium ion concentration is 10-7 M - 10-6M。
18. The use of claim 15, wherein the dockerin combination mutant 36864 interacts with mucin CohA intracellularly to construct a protein complex.
CN202010730981.0A 2020-07-27 2020-07-27 Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application Active CN111850007B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010730981.0A CN111850007B (en) 2020-07-27 2020-07-27 Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010730981.0A CN111850007B (en) 2020-07-27 2020-07-27 Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application

Publications (2)

Publication Number Publication Date
CN111850007A CN111850007A (en) 2020-10-30
CN111850007B true CN111850007B (en) 2022-03-29

Family

ID=72947323

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010730981.0A Active CN111850007B (en) 2020-07-27 2020-07-27 Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application

Country Status (1)

Country Link
CN (1) CN111850007B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111850004B (en) * 2020-07-27 2022-04-22 齐鲁工业大学 Cellulosomal dockerin mutant 36740 with improved activity and application thereof
CN115011621A (en) * 2022-06-27 2022-09-06 齐鲁工业大学 Recombinant protein and method for detecting substrate through fluorescence
CN114875052B (en) * 2022-06-27 2023-11-14 齐鲁工业大学 Fusion protein capable of detecting hyaluronic acid and detection method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016067A2 (en) * 2008-08-07 2010-02-11 Yeda Research And Development Co. Ltd. Affinity purification by cohesin-dockerin interaction
WO2012122396A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CN103025879A (en) * 2010-07-20 2013-04-03 沃尔夫冈·H·施瓦茨 Artificial cellulosome and the use of the same for enzymatic breakdown of resilient substrates
CN109055439A (en) * 2018-08-17 2018-12-21 中国科学院青岛生物能源与过程研究所 The method that ethyl alcohol is prepared using lignocellulosic
CN111848757A (en) * 2020-07-27 2020-10-30 齐鲁工业大学 Cellulosome docking protein combined mutant 36862 suitable for low calcium ion concentration and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5307716B2 (en) * 2007-08-27 2013-10-02 シスメックス株式会社 Dockin polypeptide and method for purifying recombinant fusion protein using the same
CN101851656B (en) * 2010-04-19 2012-08-29 中国科学院青岛生物能源与过程研究所 Method for producing cellulosic ethanol
KR20130036246A (en) * 2010-05-07 2013-04-11 베일러 리서치 인스티튜트 Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016067A2 (en) * 2008-08-07 2010-02-11 Yeda Research And Development Co. Ltd. Affinity purification by cohesin-dockerin interaction
CN103025879A (en) * 2010-07-20 2013-04-03 沃尔夫冈·H·施瓦茨 Artificial cellulosome and the use of the same for enzymatic breakdown of resilient substrates
WO2012122396A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
CN109055439A (en) * 2018-08-17 2018-12-21 中国科学院青岛生物能源与过程研究所 The method that ethyl alcohol is prepared using lignocellulosic
CN111848757A (en) * 2020-07-27 2020-10-30 齐鲁工业大学 Cellulosome docking protein combined mutant 36862 suitable for low calcium ion concentration and application

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chain B, Endo-1,4-beta-xylanase Y;GenBank DataBase;《GenBank DataBase》;GenBank DataBase;20121010;Accession NO：2CCL_B *
Single-molecule dissection of the high-affinity cohesin–dockerin complex;Stefan W. Stahl等;《PNAS》;pnas;20121211;第109卷(第50期);第20431-20436页 *
纤维小体关键元件胞内自组装体系构建研究;薛乐;《中国优秀硕士学位论文全文数据库》;CNKI;20210215(第02期);A006-758 *
解纤维梭菌纤维小体的研究进展;赵飞等;《化学与生物工程》;万方;20130621;第30卷(第3期);第1-5页 *

Also Published As

Publication number Publication date
CN111850007A (en) 2020-10-30

Similar Documents

Publication Publication Date Title
CN111850007B (en) Cellulosobody docking protein combination mutant 36864 applicable to low calcium ion concentration and application
CN111304232B (en) Method for purifying protein based on membrane surface fusion expression strategy and application thereof
CN111454978A (en) Surface display engineering bacterium for specifically adsorbing heavy metal lead and construction method and application thereof
CN111848758B (en) Cellulosome docking protein mutant suitable for low calcium ion concentration and application
CN109627290B (en) Alpha spiral self-assembly short peptide and application thereof in protein purification
CN111848757B (en) Cellulosome docking protein combined mutant 36862 suitable for low calcium ion concentration and application
CN111850005B (en) Cellulosome docking protein combined mutant 36863 suitable for low calcium ion concentration and application
CN114774452B (en) Construction method and application of engineering escherichia coli for adsorbing mercury ions in solution
CN113151214B (en) Protein PnlipA with lipase activity and gene and application thereof
CN112592877B (en) Recombinant escherichia coli for over-expressing lsrC gene and construction method and application thereof
CN112481282B (en) Carbohydrate binding module CBM6B protein capable of specifically recognizing xanthan gum side chain and application thereof
CN115074340A (en) Novel intein and application thereof in synthesis of human tropoelastin
CN111850006B (en) Cellulosome docking protein combined mutant 36865 suitable for low calcium ion concentration and application
CN110938645A (en) Sugarcane yellow leaf virus motor protein expression and purification method and preparation of polyclonal antiserum thereof
CN111848759B (en) Cellulosomal dockerin mutant 36741 with improved activity and application thereof
CN111850004B (en) Cellulosomal dockerin mutant 36740 with improved activity and application thereof
CN110596381A (en) Method for detecting melon aphid-borne yellowed virus and preparation of special polyclonal antibody thereof
CN113215128B (en) Method for improving activity of esterase DcaE4 and application
CN113337491B (en) Structural domain for improving high-temperature resistance stability of keratinase and application thereof
CN113122558B (en) Expression vector of membrane protein AmpG and expression and purification method thereof
CN113122561B (en) Expression vector of membrane protein SohB and expression and purification method thereof
CN114591985B (en) Mutant pectin lyase and application thereof
CN113136395A (en) Expression vector of membrane protein YcbM and expression and purification method thereof
CN101532016B (en) A section of DNA molecule, recombination expression vector containing the DNA molecule and use thereof
CN113136394A (en) Expression vector of membrane protein CcmB and expression purification method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant